Please login to the form below

Not currently logged in
Email:
Password:

anti-NGF

This page shows the latest anti-NGF news and features for those working in and with pharma, biotech and healthcare.

FDA halts study of Teva and Regeneron's pain drug fasinumab

FDA halts study of Teva and Regeneron's pain drug fasinumab

Arthropathy has been seen before with NGF inhibitors - and caused the agency to put the entire class under a clinical hold in 2011. ... Eli Lilly and partner Pfizer also remain in the race with their tanezumab anti-NGF candidate, which restarted testing

Latest news

  • Regeneron says anti-NGF fasinumab works in pain Regeneron says anti-NGF fasinumab works in pain

    That hold was subsequently relaxed to a partial hold, allowing some drugmakers to resume testing and leading to optimism that anti-NGF programmes may get back on track. ... The decision was attributed to shifting commercial priorities rather than a

  • Lilly eyes pivotal trials for pain drug tanezumab in 2015 Lilly eyes pivotal trials for pain drug tanezumab in 2015

    The antibody drug targets nerve growth factor (NGF) and - if approved - would represent a completely new drug class for chronic pain conditions, including osteoarthritis and cancer-related pain. ... In 2012 however a new partial clinical hold on the

  • J&J chief predicts 10 new pharma filings by 2017 J&J chief predicts 10 new pharma filings by 2017

    Among the pipeline projects highlighted by Gorsky are esketamine, a glutamate NMDA antagonist that he described as a "potential breakthrough medication" for treatment-resistant depression, as well as anti-CD38 antibody ... Fulranumab, an anti-nerve

  • Pfizer sales down but oncology shows promise Pfizer sales down but oncology shows promise

    There were also gains for anti-inflammatory Celebrex (celecoxib), up 11 per cent to $752m, while fibromyalgia drug Lyrica (pregabalin) cemented its position as Pfizer's biggest-selling product with a ... The company has also joined forces with Lilly to

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....